This week, two 2019 covid-19 vaccines developed in Seattle were approved by regulators outside the United States. A shooting at the University of Washington is ready to be launched in South Korea, while a shooting related to HDT bio has been approved for emergency use in India. Neilking, a researcher at the University of Washington, told geekwire earlier this month that the injection at the University of Washington was the first approved drug based on computational protein design. “For me, this is a watershed moment.”.
Clinical trials and studies:
Fred hatch researcher Jesse bloom and his colleagues published a study outlining key steps in the evolution of omicro and other 2019 coronavirus disease mutations.
The experimental treatment of prostate cancer by essa pharmaceutical company, located in the south of San Francisco and Vancouver, British Columbia, showed “preliminary antitumor activity” in early studies.
Lumithera, a Seattle area medical device company, reported experimental data on its use of a phototherapy for age-related macular degeneration.
According to a study led by the University of Wisconsin, black women are more likely to delay getting breast biopsies than white women. The results show that systematic racism may be a factor.
Approvals and transactions:
Breyanzi, an automotive T-cell cancer therapeutic instrument produced by Bristol Myers Squibb in the Seattle area, is approved for the treatment of patients in the early stage of the disease.
Arzeda, a Seattle based company that designs industrial proteins, announced a partnership with w.l.gore&amp, a global materials science company; Associates.
Boda, headquartered in Vancouver, British Columbia, developed nicotine delivery devices and sold $100.5 million to Altria group.
Fund:
Patrick Boyle, a bioengineer at the University of Washington, received a $2.9 million grant from the National Institutes of health to create a tool that combines medical imaging with computational methods to assess the risk of stroke in patients with heart disease.
Dianne Xiao, assistant professor of chemistry in Wisconsin, won a $600000 prize from the Arnold and Mabel Beckman foundation for her research on catalysis, clean energy and materials.
The Washington Research Foundation donated $1.65 million to support graduate students at the University of Washington and Washington State University.
The Steve Gleason Neuroscience Institute of WSU provided four seed funds of $160000 to scientists studying neurodegenerative diseases.
Technical action:
Timothy dellit temporarily served as CEO, executive vice president of medical affairs and Dean of UW medicine. He replaced Paul Ramsey, who retired this summer.
Kineta has a new chief scientific officer Thierry guillaudeux, and zymeworks, who hired Paul Moore, has a new chief scientific officer.
William canestaro will become a researcher of the German Marshall Fund and continue to serve as the managing director of the Washington research foundation.
If you missed:
Affini-t therapeutics announced a partnership with metagenomi, a gene editing company. Affini-t has business in Seattle and will apply metagenomi’s technology to T cell receptor therapy for oncogenes.
The medical innovation collaboration and Amazon Web Services launched an incubation program to prepare start-ups from Europe, Africa and the Middle East to understand and enter the U.S. medical market.